Luca Santarelli © Therachon

Swiss rare genetic diseases company Therachon AG has named Luca Santarelli Chief Executive Officer and Director. Santarelli brings widespred experience from his role as Venture Partner at Versant Ventures, founding investor of Therachon.

Malte Peters; @Morphosys AG

Malte Peters will leave Sandoz to take over as Chief Development Officer of Morphosys AG. Peters succeeds Arndt Schottelius, who held the position for eight yeara.

Giles Campion; © Albumedix

Novozymes company Albumedix A/S has appointed Giles Campion new Chief Medical Officer. Campion will be in charge of leading the development efforts of the Danish leader in albumin-based drug delivery. 

Dennis Dionne; © Newron Pharmaceuticals

Milan-based Newron Pharmaceuticals has named Dennis Dionne Vice President Commercial Affairs. Previously, Dionne was Executive Director for Commercial Operations. He replaces Anders Haegerstrand.

Deborah Waterhouse
Deborah Waterhouse, currently Senior Vice President Primary Care, GSK US Pharmaceuticals, will take over as CEO of Viiv Healthcare. She succeeds Dominique Limet, who will step down from the post at the end of March 2017. 
Mondher Majhoubi

Co-founder of immuno-oncology start-up Innate Pharma Hervé Brailly is making room on the chair of the executive board. His successor Mondher Majhoubi transfers from AstraZeneca, where he was Senior Vice President, Therapeutic Area Head-Oncology, Global Product and Portfolio Strategy.

Matthew Kapusta
Gene therapy company uniQure NV has named Matthew Kapusta its new Chief Executive Officer. Kapusta has been interim CEO since September and also served as Chief Financial Officer for the last two years. 
Melanie Maas-Brunner, © BASF

Among other appointments, BASF has named Melanie Maas-Brunner as new President Nutrition and Health, effective April 1, 2017. Previously, Maas-Brunner held the position of Senior Vice President Performance Materials Europe.

© Autifony

Drug discovery company Confo Therapeutics has appointed John Edward Berriman as non-executive director and chairman of the board of directors. Berriman is set to take his seat on the board December 21.

John Rex, © F2G

Antifungal drug developer F2G Ltd has appointed distinguished research scientist John Rex to the position of Chief Medical Officer.